SCHEDULE 13G: Titan Trust 2024 I Discloses 7.69% Stake in DarioHealth Corp. via Warrant Exercise

Titan Trust 2024 I has reported a beneficial ownership of 7.69% in DarioHealth Corp., primarily through the cashless exercise of warrants.

Summary

• Titan Trust 2024 I beneficially owns 2,500,100 shares of DarioHealth Corp. common stock.
• This ownership represents 7.69% of the company's outstanding common stock.
• The stake originated from a warrant dated February 15, 2024, which was exercisable within 60 days after September 12, 2024.
• On November 14, 2024, 2,499,828 shares were issued to Titan Trust 2024 I through a cashless exercise of this warrant.
• The percentage ownership was calculated based on 30,028,280 shares of Common Stock outstanding as of August 5, 2024, as reported in DarioHealth Corp.'s Quarterly Report on Form 10-Q, plus the 2,500,100 shares reported in this filing.
• WhiteHawk Capital Partners LP, as the Administrator of Titan Trust 2024 I, may be deemed to beneficially own these securities.

Sentiment

Score: 7

Explanation: The disclosure of a significant institutional stake (7.69%) by Titan Trust 2024 I, resulting from a warrant exercise, is generally a positive signal for DarioHealth Corp., indicating investor confidence and a solidification of an equity position. While it's a routine regulatory disclosure, the underlying action of taking a large stake is positive.

Positives

• A significant institutional investor, Titan Trust 2024 I, has taken a substantial stake (7.69%) in DarioHealth Corp., which can signal confidence in the company's future prospects.
• The exercise of warrants indicates a conversion of potential equity into actual shares, solidifying the investor's long-term position in the company.

Future Outlook

This document does not contain forward-looking statements or guidance from DarioHealth Corp. management; it is a disclosure of beneficial ownership by an investor.

Management Comments

• Titan Trust 2024 I certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by a trust in DarioHealth Corp., a company operating in the digital health sector. Such substantial institutional investments are common in the healthcare technology industry as companies seek capital for growth and expansion. A significant stake by an institutional investor can be viewed positively, suggesting external validation of the company's potential and business model.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) required when an entity acquires beneficial ownership exceeding 5% of a public company's outstanding shares. There are no specific financial results or operational metrics within this filing to compare to broader industry standards.
• The 7.69% ownership stake is a significant minority position, which is a common level for institutional investors taking strategic or passive positions in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a substantial stake could be viewed positively, potentially increasing investor confidence and demand for shares.

Key Dates

Keywords

DarioHealth Corp., Titan Trust 2024 I, Schedule 13G, Beneficial Ownership, Warrant Exercise, Common Stock, Equity Stake, Institutional Investor, WhiteHawk Capital Partners